Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in k-ras-2 were seen in 25% and 19% of RC and NRC tumors, respectively, most frequently in adenocarcinomas.
|
12527710 |
2003 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inactivation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas.
|
14511407 |
2004 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, the authors suggest that the cooperative effects of Ha-ras and fes oncogenes are especially important in the carcinogenesis of adenocarcinoma.
|
1310887 |
1992 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Ki-ras gene mutation was detected in 12 of 20 (60%) mucin-producing adenocarcinomas.
|
9234384 |
1997 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
KRAS2 gene mutations are found in 75-90% of infiltrating pancreatic ductal adenocarcinomas but can also be present with other nonneoplastic pancreatic diseases.
|
18075308 |
2008 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the other tumors, more complex aberrations were visualized, including two inversions in 12q with a common breakpoint between MDM2 and D12S332 in a pleomorphic adenoma, amplification of MDM2 and CDK4 in ring chromosomes from a malignant fibrous histiocytoma, and amplification of KRAS2 together with other unbalanced rearrangements in two pancreatic adenocarcinomas.
|
10862042 |
2000 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Meanwhile, 11 (58 per cent) serrated adenomas and six (60 per cent) adenocarcinomas in/with serrated adenomas had Ki-ras gene mutations, as also did 9 of 23 (39 per cent) hyperplastic nodules, 3 of 4 (75 per cent) hyperplastic polyps, and 12 of 29 (41 per cent) tubular adenomas.
|
9924427 |
1998 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seventy-seven pancreatic adenocarcinomas (60 Spanish and 17 Italian) were tested for Ki-ras gene mutations by analysis of polymerase chain reaction amplified sequences.
|
8157353 |
1994 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HPV DNA type 16 or 18 in cervical adenocarcinomas was detected in 35% of cases by PCR and in 29% by Southern blotting, and, in contrast to the p53 mutations, the majority of cases with the HPV DNA were at a relatively early clinical stage with low-grade histological atypia. c-Ki-ras gene mutation was detected in only 4% of cervical adenocarcinomas.
|
7960232 |
1994 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung.
|
7910096 |
1994 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutant c-K-ras genes were detected in about 75% of adenocarcinomas of the pancreas (n = 84); 40% of adenomas (n = 72) and carcinomas (n = 244) of the colon end rectum; 30% of carcinomas of the bile duct (n = 19); 25% of carcinomas of the lung (n = 92), and in lower frequency in other carcinomas, including liver, stomach, and kidney.
|
1685441 |
1991 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the 16 samples adequate for PCR/RFLP analysis, a c-Ki-ras gene mutation was detected in 11 (92%) of 12 adenocarcinomas.
|
7902444 |
1993 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine whether the molecular lesion in ovarian carcinoma was a genetic rearrangement or amplification of expressed oncogenes, we examined the myc, Ha-ras, Ki-ras, and fos oncogenes in 14 serous adenocarcinomas of the ovary using molecular hybridization techniques.
|
2801838 |
1989 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas.
|
2674856 |
1989 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status.
|
12696070 |
2003 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, point mutations of the c-Ki-ras gene were detected in 1 gastric-type adenocarcinoma and 2 intestinal-type adenocarcinomas, suggesting the occurrence of a common genetic abnormality.
|
7903667 |
1993 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with morphologic and molecular features akin to invasive ductal carcinoma of the breast, including HER2 gene amplification, mutations of TP53, PIK3CA, and HRAS and loss or mutation of PTEN.
|
29076877 |
2018 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
If a mutation of c-K-ras 2 gene is an important component in the formation of adenocarcinoma, these results did not confirm the successive development from adenomas with severe atypia to advanced carcinomas as the main route for colorectal carcinogenesis in familial adenomatous polyposis patients.
|
1333425 |
1992 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The c-Ki-ras gene was hypomethylated to a lesser extent in two colonic adenocarcinomas.
|
6187346 |
1983 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The combined HR was 1.35 (95% CI: 1.16-1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26-2.02) and in studies using PCR (HR 1.40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34).
|
15597105 |
2005 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight pancreatic adenocarcinomas in the range 1.2-3 cm were analyzed for c-K-ras mutation at codon 12 by amplifying the c-K-ras gene around codon 12 out of paraffin-embedded tissue sections using the polymerase chain reaction. c-K-ras mutations were detected by allele-specific oligonucleotide hybridization.
|
8190717 |
1994 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased copy number of the ERBB2 (1 of 22), GATA4 (1 of 22), KRAS (2 of 22), C-MYC (1 of 22), CCNE1 (2 of 22), and CCND1 (2 of 22) genes was also observed in one or more Barrett's adenocarcinomas with HGD.
|
14581353 |
2003 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
KRAS2 mutations were found in four out of 19 (21%) Barrett's adenocarcinomas examined and in three cases of HGIN (11%).
|
14724583 |
2004 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we report that loss of heterozygosity (LOH) of chromosome 12p was detected in approximately 50% of human lung adenocarcinomas and large cell carcinomas, and Kras2 mutations were detected at codon 12 in approximately 40% of adenocarcinomas and large cell carcinomas.
|
12606951 |
2003 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight of 22 prostate adenocarcinomas (three of nine (33.3%) from the ventral lobe and five of 13 (38.5%) from the dorsolateral lobe, including three transplantable tumors) and one of 11 seminal vesicle adenocarcinomas (9.1%) demonstrated point mutations in the Ki-ras gene.
|
7766307 |
1995 |